Prosight Management, LP
DALLAS, TX · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$515.5M2026 Q3
Positions32
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.70.6%
What Changed This Quarter?
Top Holdings
LKFT
Lakefront Biotherapeutics
11.5%
STTK
Shattuck Labs
10.1%
JANX
Janux Therapeutics
9.9%
NKTR
Nektar Therapeutics
9.2%
ABVX
Abivax S.A.
7.2%
INSM
Insmed
5.3%
BSX
Boston Scientific
4.7%
IRTC
iRhythm
4.4%
New / Increased
9 new · 11 increased
PRVANEW
Privia Health
4.0%
DNLINEW
Denali Therapeutics
2.2%
PRAXNEW
Praxis Precision Medicines
2.1%
HQYNEW
Healthequity
2.0%
BBIONEW
Bridgebio Pharma
1.9%
ABVX
Abivax
7.2%
+250.9%
STTK
Shattuck Labs
10.1%
+28.4%
MLYS
Mineralys Therapeutics
3.9%
+77.9%
Reduced / Exited
12 reduced · 13 sold out
BSX
Boston Scientific
4.7%
-56.7%
INSM
Insmed
5.3%
-36.6%
ALNY
Alnylam Pharmaceuticals
1.8%
-62.3%
JANX
Janux Therapeutics
9.9%
-22.6%
Adc Therapeut…
Adc Therapeutics
0.1%
-94.9%
VEEVEXIT
Veeva Sys
3.2%
CRNXGBPEXIT
Crinetics Pharmaceuticals In
2.4%
ICUIEXIT
Icu Med
1.3%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.